SBE-13 HCl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 406445

CAS#: 1052532-15-6

Description: SBE-13 is a selective inhibitor of PLK1 (IC50 values are 200 pM, 875 nM and 66 μ M for PLK1, PLK3 and PLK2 respectively).

Price and Availability

Size Price Shipping out time Quantity
50mg USD 450 2 Weeks
100mg USD 850 2 Weeks
200mg USD 1450 2 Weeks
500mg USD 1950 2 Weeks
1g USD 3250 2 Weeks
2g USD 4950 2 Weeks
5g USD 9450 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-01-26. Prices are subject to change without notice.

SBE-13 HCl, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 406445
Name: SBE-13 HCl
CAS#: 1052532-15-6
Chemical Formula: C24H27ClN2O4
Exact Mass: 442.16594
Molecular Weight: 442.93518
Elemental Analysis: C, 65.08; H, 6.14; Cl, 8.00; N, 6.32; O, 14.45

Synonym: SBE13; SBE 13; SBE13; SBE-13 HCl.

IUPAC/Chemical Name: N-(4-((6-chloropyridin-3-yl)methoxy)-3-methoxybenzyl)-2-(3,4-dimethoxyphenyl)ethanamine hydrochloride


InChi Code: InChI=1S/C24H27ClN2O4.ClH/c1-28-20-7-4-17(12-22(20)29-2)10-11-26-14-18-5-8-21(23(13-18)30-3)31-16-19-6-9-24(25)27-15-19;/h4-9,12-13,15,26H,10-11,14,16H2,1-3H3;1H


Technical Data

white solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:

Additional Information


1: Eckerdt F. Polo-like kinase 1 inhibitors SBE13 and BI 2536 induce different responses in primary cells. Cell Cycle. 2011 Apr 1;10(7):1027-8. Epub 2011 Apr 1. PubMed PMID: 21415595.

2: Posern G. Should I stall or should I cycle? An inhibitor for Polo-like Kinase 1 with distinct roles in primary cells. Cell Cycle. 2011 Apr 1;10(7):1029-30. Epub 2011 Apr 1. PubMed PMID: 21412046.

3: Keppner S, Proschak E, Schneider G, Spänkuch B. Fate of primary cells at the G1/S boundary after polo-like kinase 1 inhibition by SBE13. Cell Cycle. 2011 Feb 15;10(4):708-20. Epub 2011 Feb 15. PubMed PMID: 21301227.

4: Eckerdt F. Freezing Polo in its sleep: targeting the inactive conformation of Polo-like kinase 1 in cancer cells. Cell Cycle. 2010 Mar 1;9(5):862. Epub 2010 Mar 1. PubMed PMID: 20348843.

5: Keppner S, Proschak E, Kaufmann M, Strebhardt K, Schneider G, Spänkuch B. Biological impact of freezing Plk1 in its inactive conformation in cancer cells. Cell Cycle. 2010 Feb 15;9(4):761-73. Epub 2010 Feb 16. PubMed PMID: 20139717.

6: Liu X. SBE13 joins the family of Polo-like kinase 1 (Plk1) inhibitors. Cell Cycle. 2010 Feb 1;9(3):445-6. Epub 2010 Feb 1. PubMed PMID: 20130451.

7: Keppner S, Proschak E, Schneider G, Spänkuch B. Identification and validation of a potent type II inhibitor of inactive polo-like kinase 1. ChemMedChem. 2009 Nov;4(11):1806-9. doi: 10.1002/cmdc.200900338. PubMed PMID: 19746360.